Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Melanoma BRAF V600E/K Mutated”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Testing effectiveness (Phase 2)Ended earlyNCT05926960
What this trial is testing

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Who this might be right for
Melanoma
Pfizer 38
Testing effectiveness (Phase 2)Looking for participantsNCT06887088
What this trial is testing

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Who this might be right for
Melanoma BRAF V600E/K MutatedMelanoma and Brain Metastases
Grupo Español Multidisciplinar de Melanoma 33
Testing effectiveness (Phase 2)Study completedNCT01928940
What this trial is testing

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Who this might be right for
Solid Tumours
GlaxoSmithKline 12
Testing effectiveness (Phase 2)Study completedNCT02392871
What this trial is testing

Radiotherapy & Combi in Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Melanoma and Skin Cancer Trials Limited 10
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Large-scale testing (Phase 3)Active Not RecruitingNCT05270044
What this trial is testing

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Who this might be right for
Melanoma
Pierre Fabre Medicament 815
Large-scale testing (Phase 3)Active Not RecruitingNCT04657991
What this trial is testing

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Pfizer 257
Early research (Phase 1)Study completedNCT01767454
What this trial is testing

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Who this might be right for
Solid Tumours
GlaxoSmithKline 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT06784648
What this trial is testing

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Who this might be right for
Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K Mutated+7 more
BioInvent International AB 35
Post-approval studies (Phase 4)WithdrawnNCT07092410
What this trial is testing

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Who this might be right for
Melanoma BRAF V600E/K Mutated
SRH Wald-Klinikum Gera GmbH
Large-scale testing (Phase 3)Study completedNCT01597908
What this trial is testing

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 704
Testing effectiveness (Phase 2)UnknownNCT02202200
What this trial is testing

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

Who this might be right for
Melanoma BRAF V600E/K MutatedCDNKN2A Loss Defined
Assistance Publique - Hôpitaux de Paris 40
Not applicableNo Longer AvailableNCT02416232
What this trial is testing

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Testing effectiveness (Phase 2)UnknownNCT05263453
What this trial is testing

HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Who this might be right for
Melanoma
Shanghai Kechow Pharma, Inc. 104
Testing effectiveness (Phase 2)Ended earlyNCT02410863
What this trial is testing

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

Who this might be right for
Malignant Melanoma
Prof. Dr. med. Dirk Schadendorf 10